Target family: Folate biosynthesis enzymes (type: other_protein)
Target: Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase

Ligand: P218 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Transgenic pyrimethamine-resistant plasmodium falciparum reveals transmission-blocking potency of P218, a novel antifolate candidate drug.
Published in: Int J Parasitol

Ligand: P218 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.25 pIC50
Reference (Journal): Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.
Published in: Proc Natl Acad Sci USA

Ligand: P218 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pEC50
Reference (Journal): A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.
Published in: Nat Commun

Ligand: P218 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.34000015258789 pIC50
Reference (Journal): Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.
Published in: Proc Natl Acad Sci USA

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 4 pIC50
Reference (Journal): Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.
Published in: Proc Natl Acad Sci USA

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.350000381469727 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Journal): Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.
Published in: Proc Natl Acad Sci USA

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.369999885559082 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 8.34000015258789 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 5.079999923706055 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: pyrimethamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 5.170000076293945 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med